Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher

Inclusion criteria

• Adult between the ages of 18 and 70.
• Patient who has cough symptom caused by following diseases: chronic bronchitis, bronchiectasis, gastroesophageal reflux disease, postnasal drip syndrome caused by rhinitis, sinusitis, rhinopharyngitis, rhinolaryngitis.
• Patient requiring internal treatment due to cough symptom, who has coughing more than 3 weeks.
• patient who will continue to cough more than 1 week.(by physician's judgment)
• Patient who decided to participate in this clinical trial at his(her) own will and agreed in written letter of consent.
• Patient who is trustworthy, ready for cooperation and observing the restrictions during the trial period.

Exclusion criteria

• Patient who is accompanied by the seriously abnormal symptom in respiratory system, such as Acute infectious Pulmonary Disease, Tuberculosis.
• Patient who has clinical history of sensitivity to Xanthine drug.
• Patient who has Peptic Ulcer or Asthma (Except Cicatrix)
• Patient whose liver or kidney function is seriously abnormal: Including the cases of sGOT, sGPT, bilirubin and blood creatinine value exceeding twice of their upper normal limit.
• Patient whose heart function is abnormal: including the case of showing abnormal EKG test value that is clinically significant.
• Patient who has experience to have participated in other clinical trial within two months before starting the trial.
• Pregnant woman, lactating woman.
• patient who has convulsion or alcoholism.
• patient who take medicines which can not use combination with AG1321001.